Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 318,893 Shares of Stock

Key Points

• Director Stephen Bloch sold 318,893 Liquidia shares on Monday, May 11, at an average price of $50.23, generating about $16.0 million. After the sale, he still owned 1.87 million shares, and his stake fell by 14.57%.
• Liquidia reported stronger-than-expected quarterly results, posting EPS of $0.52 versus estimates of $0.41 and revenue of $132.87 million versus expectations of $119.44 million. Revenue also surged 4,187.1% year over year.
• The stock has rallied sharply amid upbeat sentiment, recently trading near its 52-week high of $57.80, while analysts have mostly turned constructive with several price-target increases and a consensus “Moderate Buy” rating.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 318,893 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the sale, the director owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Liquidia Price Performance

NASDAQ LQDA traded up $0.99 during trading hours on Wednesday, reaching $57.59. 2,267,546 shares of the company's stock were exchanged, compared to its average volume of 1,714,195. The stock has a market cap of $5.12 billion, a PE ratio of 411.39 and a beta of 0.41. Liquidia Corporation has a one year low of $11.85 and a one year high of $57.80. The firm has a fifty day moving average of $38.17 and a 200-day moving average of $35.29. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 81.61% and a net margin of 7.74%.The firm's revenue was up 4187.1% compared to the same quarter last year. On average, equities research analysts predict that Liquidia Corporation will post 2.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Farallon Capital Management LLC boosted its position in shares of Liquidia by 1.1% in the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company's stock worth $298,547,000 after purchasing an additional 90,400 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company's stock worth $138,439,000 after purchasing an additional 52,671 shares during the last quarter. Opaleye Management Inc. boosted its position in shares of Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company's stock worth $30,838,000 after purchasing an additional 215,000 shares during the last quarter. Caprock Group LLC boosted its position in shares of Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company's stock worth $61,527,000 after purchasing an additional 151,832 shares during the last quarter. Finally, TCG Crossover Management LLC bought a new position in shares of Liquidia in the 3rd quarter worth $38,887,000. 64.54% of the stock is currently owned by institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s Q1 results topped expectations on both earnings and revenue, with management highlighting record growth and continued profitability, reinforcing confidence in the company’s commercial rollout. Liquidia Corp (LQDA) Q1 2026 Earnings Call Highlights: Record Growth and Strategic Expansion
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and targeted at least $1 billion in net revenue by 2027, signaling strong launch momentum and a sizable growth runway. Liquidia targets at least $1B net revenue in 2027 as YUTREPIA Q1 net product sales rise 44% sequentially
• Positive Sentiment: Several analysts turned more constructive after earnings, including Needham raising its target to $70, BTIG lifting its target to $59, and Wells Fargo setting a $62 target, all of which should support investor sentiment. Liquidia NASDAQ: LQDA Price Target Raised to $70.00 at Needham & Company LLC
• Positive Sentiment: LQDA was added to Zacks Rank #1 Strong Buy momentum lists, which can draw additional short-term trading interest from momentum-focused investors. New Strong Buy Stocks for May 13th
• Neutral Sentiment: Liquidia presented at the Bank of America Global Healthcare Conference, which keeps the company in front of investors but did not include a clearly new operational catalyst in the headline. Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: CEO Roger Jeffs sold shares under a pre-arranged 10b5-1 plan; the sale is not necessarily a negative signal, but insider selling can still attract attention. SEC filing
• Negative Sentiment: One recent bearish note argued that YUTREPIA’s launch upside may be nearing a ceiling, suggesting future share gains could become harder to achieve. Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Analysts Set New Price Targets

A number of brokerages have commented on LQDA. Lifesci Capital upgraded Liquidia to a "strong-buy" rating in a research report on Thursday, March 5th. BTIG Research increased their price objective on Liquidia from $50.00 to $59.00 and gave the company a "buy" rating in a research report on Monday. Wall Street Zen upgraded Liquidia from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Oppenheimer increased their price objective on Liquidia from $16.00 to $19.00 and gave the company an "underperform" rating in a research report on Thursday, March 12th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Liquidia currently has a consensus rating of "Moderate Buy" and an average price target of $49.33.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.